Equities
Health CareMedical Equipment and Services
  • Price (EUR)20.90
  • Today's Change0.000 / 0.00%
  • Shares traded450.00
  • 1 Year change-33.44%
  • Beta0.7642
Data delayed at least 15 minutes, as of Feb 18 2026 09:23 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Stratec SE is a Germany-based company. The Company is engaged in development and manufacture of analyzer systems, and it is also performing and managing administrative and organizational tasks for laboratory markets. Stratec is providing automation solutions and instrumentation of biochemical processes using hardware and software for in-vitro diagnostics and life science companies. It also developing and integrating instrumentation, complex consumables and software by covering virtually the entire value chain for specification, design, manufacture and approval of complex analyzer system solutions.

  • Revenue in EUR (TTM)256.91m
  • Net income in EUR15.65m
  • Incorporated2018
  • Employees1.42k
  • Location
    Stratec SeGewerbestr. 37BIRKENFELD 75217GermanyDEU
  • Phone+49 708279160
  • Fax+49 70 827916999
  • Websitehttps://www.stratec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nordhealth As50.26m-10.65m136.47m450.00--3.66--2.72-1.52-1.527.189.320.6188--8.101,381,440.00-13.11---14.99--82.95---21.19------0.00--24.03--31.06------
Oncosem Onkolojik Sistemlr Sny v Tcrt AS11.27m287.16k140.83m358.00490.4119.90101.8912.490.6240.62424.4915.371.264.614.262,000,638.003.20-7.804.30-10.6836.3933.562.55-8.411.863.040.1562--7.8550.9448.65--10.14--
Stille AB53.41m5.24m155.98m220.0029.732.3418.592.926.216.2163.8078.870.55231.716.912,580,132.005.426.006.186.8450.7348.819.819.861.95-------0.407231.82-4.3146.43-2.68--
Carasent AB (publ)32.35m3.26m159.91m196.0047.001.9917.244.940.500.504.8511.800.3416--7.941,754,184.003.44--3.89--84.06--10.08------0.038--24.91--182.04------
Nyxoah SA5.64m-83.72m162.21m184.00--2.78--28.77-2.24-2.240.15091.360.04770.35432.1530,646.74-70.84-27.03-83.81-29.8164.3663.56-1,484.66-1,347.971.41--0.2934--3.98---37.08--86.96--
Detection Technology Oyj-100.00bn-100.00bn162.68m497.00--2.08----------5.34----------8.02--10.04--46.64--7.502.30----61.79-6.044.37-42.04-0.892-13.111.39
Guerbet SA809.67m7.74m173.18m2.91k33.710.4592.460.21390.40640.406464.2529.850.78650.5464.90278,715.700.46190.920.60551.2078.0376.510.58731.191.031.460.517264.797.050.5853-32.61-15.50-0.8569--
Median Technologies SA23.31m-21.99m183.96m211.00------7.89-1.16-1.161.23-2.080.8894-12.983.9296,717.84-83.91-60.70---232.35102.73102.32-94.35-97.730.3543-26.56----3.2520.72-9.83--43.77--
Prim SA240.47m14.55m216.36m954.0013.841.638.480.89980.91760.917614.137.801.171.974.17251,008.807.096.2710.408.5038.7737.706.055.851.20144.870.139963.107.689.08-13.83-0.536613.506.35
Tristel Plc53.18m7.60m226.26m265.0029.835.9720.944.250.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Onward Medical NV1.11m-38.65m231.32m102.00--6.65--208.02-0.866-0.8660.02490.62090.0215--9.1110,901.96-74.86-55.03-92.84-61.1977.16---3,475.81-39,652.374.30-17.130.352--236.76--1.26--3.88--
Affluent Medical SAS4.12m-14.74m235.20m76.00--7.40--57.11-0.3759-0.37590.10510.53650.0709--0.954159,681.16-25.40-23.76-32.61-27.591.34-226.93-358.01-1,815.40---924.300.5030------5.84------
Stratec SE256.91m15.65m254.10m1.42k16.231.067.370.98911.291.2921.1319.750.58251.325.65177,177.203.556.724.247.9629.0928.416.099.631.656.850.355237.35-4.733.764.242.35-7.49-6.51
Medistim ASA59.19m12.61m305.18m154.0024.148.2120.405.167.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB71.41m14.40m335.27m236.0023.284.0118.524.706.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
Data as of Feb 18 2026. Currency figures normalised to Stratec Se's reporting currency: Euro EUR

Institutional shareholders

27.05%Per cent of shares held by top holders
HolderShares% Held
Brown Capital Management LLCas of 30 Sep 20251.09m8.99%
Union Investment Privatfonds GmbHas of 27 Mar 2025464.95k3.82%
Juno Investment Partners BVas of 30 Sep 2025418.59k3.44%
Janus Henderson Investors UK Ltd.as of 31 Dec 2025304.67k2.51%
Candriam Belgium SAas of 31 Dec 2025183.82k1.51%
Invesco Advisers, Inc.as of 22 Jan 2025180.57k1.49%
UBS Asset Management Switzerland AGas of 31 Oct 2025180.00k1.48%
Financi�re de l'�chiquier SAas of 30 Sep 2024164.44k1.35%
BNP Paribas Asset Management Europe SASas of 30 Jan 2026159.29k1.31%
Investor Asset Management BVas of 06 Feb 2026139.50k1.15%
More ▼
Data from 30 Sep 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.